{
    "title": "Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca.",
    "doc_id": "22540843",
    "writer": "Janero DR.",
    "year": "2012",
    "summary": "Efficiency and productivity shortfalls conspire with subpar economic return to stigmatize the pharmaceutical industry and jeopardize its viability. This complex and costly innovation-to-commercialization failure, the formidable associated costs, and the relevance of variou â€¦",
    "abstract": "Efficiency and productivity shortfalls conspire with subpar economic return to stigmatize the pharmaceutical industry and jeopardize its viability. This complex and costly innovation-to-commercialization failure, the formidable associated costs, and the relevance of various core competencies endemic to universities, the pharmaceutical industry, and government have been major drivers for establishing preclinical drug-discovery alliances involving these constituencies. Such cross-sector alliances have the potential to help restore at least some of the industry's former health by militating risk, enhancing productivity, and improving the quantity/quality of development candidates. This Editorial will highlight certain characteristics of pharma-industry and non-industrial settings that can jeopardize the effectiveness of these sectors for unified preclinical discovery campaigns capable of generating well-characterized drug candidates that merit human testing. Based on decades of research and development (R&D) and business experience spanning international big-pharma, biotechnology, and academic spheres, the author opines that a synergistic lingua franca is required among involved constituencies in order for such cross-sector discovery alliances to emerge as robust drug-discovery engines fueled by joint intellectual effort. Technology-transfer professionals, postdoctoral trainees, and consultants are discussed as resources for helping establish the university-industry-government triumvirate as a normative innovation network for preclinical drug discovery and development in the 21st century.",
    "link": "https://pubmed.ncbi.nlm.nih.gov/22540843/",
    "clean_text": "productive university industry and government relationships in preclinical drug discovery and development considerations toward a synergistic lingua franca efficiency and productivity shortfalls conspire with subpar economic return to stigmatize the pharmaceutical industry and jeopardize its viability this complex and costly innovation to commercialization failure the formidable associated costs and the relevance of variou efficiency and productivity shortfalls conspire with subpar economic return to stigmatize the pharmaceutical industry and jeopardize its viability this complex and costly innovation to commercialization failure the formidable associated costs and the relevance of various core competencies endemic to universities the pharmaceutical industry and government have been major drivers for establishing preclinical drug discovery alliances involving these constituencies such cross sector alliances have the potential to help restore at least some of the industry s former health by militating risk enhancing productivity and improving the quantity quality of development candidates this editorial will highlight certain characteristics of pharma industry and non industrial settings that can jeopardize the effectiveness of these sectors for unified preclinical discovery campaigns capable of generating well characterized drug candidates that merit human testing based on decades of research and development r d and business experience spanning international big pharma biotechnology and academic spheres the author opines that a synergistic lingua franca is required among involved constituencies in order for such cross sector discovery alliances to emerge as robust drug discovery engines fueled by joint intellectual effort technology transfer professionals postdoctoral trainees and consultants are discussed as resources for helping establish the university industry government triumvirate as a normative innovation network for preclinical drug discovery and development in the st century"
}